News

Latest News

Press Releases

August 3, 2023

Perfuse Therapeutics Announces Initiation of Enrollment to the Phase 2A Clinical Trial of PER001 Intravitreal Implant in Diabetic Retinopathy

Press Releases

July 20, 2023

Perfuse Therapeutics Announces Initiation of Enrollment to Ph2a portion of the Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

Press Releases

April 4, 2023

Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

Publications & Abstracts

Pharmacodynamic response of optic nerve head (ONH) vasculature measured by OCT-angiography (OCTA) after administration of the endothelin receptor antagonist PER-001
Brad Fortune; Grant Cull; Crystal Jadach; Kristine Ly; Michaela Dunn; Dawn Jennings; Trinity Holthausen; Howard Lockwood; Stuart Keith Gardiner; Lin Wang; Jennifer Wilk; Juan Reynaud

Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3496. doi:

Pharmacodynamic response of optic nerve head (ONH) tissue blood flow measured by laser speckle flowgraphy (LSFG) after administration of PER-001, an endothelin receptor antagonist
Grant Cull; Crystal Jadach; Juan Reynaud; Kristine Ly; Michaela Dunn; Dawn Jennings; Trinity Holthausen; Howard Lockwood; Stuart Keith Gardiner; Lin Wang; Jennifer Wilk; Brad Fortune

Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4029 – A0414. doi: